ClinicalTrials.gg
CompletedNCT06128733Updated Jan 13, 2026

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

A Phase 1/2 interventional study of Pentavalent Meningococcal ABCYW vaccine and MenACYW conjugate vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 47 sites in 2 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,215
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Study summary

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents.

The study duration will be up to 12 months for all participants.

Read the detailed description

The study duration will be approximately 12 months for all participants

02

Conditions studied

  • Meningococcal Immunisation
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: - Aged 18 to 25 years or 10 to 17 years on the day of inclusion

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgment of the Investigator.
  • Participants who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine at least 4 years prior to study enrollment Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
  • Known or suspected congenital or acquired immunodeficiency
  • History of any Neisseria meningitidis infection
  • At high risk for meningococcal infection during the study
  • Individuals with active tuberculosis
  • History of Guillain-Barré syndrome
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,215 participants (actual)

Study arms

  • Experimental
    Group 1: MenPenta Formulation 1

    Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo

    Biological: Pentavalent Meningococcal ABCYW vaccine · Biological: Placebo

  • Experimental
    Group 2: MenPenta Formulation 2

    Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo

    Biological: Pentavalent Meningococcal ABCYW vaccine · Biological: Placebo

  • Active comparator
    Group 3: Bexsero® + Menveo®

    Participants (ACWY naive and primed adults or adolescents) will receive injections of Bexsero® + Menveo® vaccine

    Biological: Meningococcal group B vaccine · Biological: MenACYW conjugate vaccine

  • Active comparator
    Group 4: Trumenba® + Menveo®

    Participants (ACWY naive and primed adults or adolescents) will receive injections of Trumenba® + Menveo® vaccine

    Biological: Meningococcal group B vaccine · Biological: MenACYW conjugate vaccine

  • Active comparator
    Group 5: MenQuadfi®

    Participants (ACWY naive and primed adults or adolescents) will receive injections of MenQuadfi® vaccine and placebo

    Biological: MenACYW conjugate vaccine · Biological: Placebo

  • Experimental
    Group 6: Sanofi MenB

    Participants (ACWY naive and primed adults or adolescents) will receive injections of SP MenB vaccine and placebo

    Biological: Meningococcal group B vaccine · Biological: Placebo

  • Active comparator
    Group 7: PENBRAYA

    Participants (ACWY naive and primed adolescents) will receive injections of PENBRAYA vaccine and placebo

    Biological: MenABCYW conjugate vaccine

Interventions

  • BiologicalPentavalent Meningococcal ABCYW vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

    Also known as: MenPenta

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

    Also known as: MenQuadFi®

  • Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

    Also known as: Bexsero®

  • Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

    Also known as: Trumenba®

  • Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

    Also known as: Sanofi MenB

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)

    Also known as: Menveo®

  • BiologicalPlacebo

    Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

  • BiologicalMenABCYW conjugate vaccine

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)

    Also known as: PENBRAYATM

06

What researchers measure

Primary outcomes

  1. Number of participants with immediate adverse events (AEs)

    Unsolicited systemic AEs that occur within 30 minutes after vaccination

    Time frame: Within 30 minutes after each vaccination

  2. Number of participants with solicited injection site reactions or systemic reactions

    Pre-defined solicited injection site reactions and systemic reactions that are pre-listed in the diary cards and CRF

    Time frame: Within 7 days after each vaccination

  3. Number of participants with unsolicited AEs

    Non-serious AEs other than solicited reactions

    Time frame: Within 30 days after each vaccination

  4. Number of participants with serious adverse events (SAEs)

    SAEs (including adverse events of special interest \[AESIs\]) reported throughout the study

    Time frame: From baseline up to 12 months

  5. Number of participants with medically attended adverse events (MAAEs)

    An MAAE is a new onset or a worsening of a condition that prompts the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or Emergency Department

    Time frame: From baseline up to 12 months

  6. Number of participants with out-of-range biological test results

    Time frame: Before each vaccination up to 7 days after primary vaccination visits in the sentinel cohorts (the first 5 participants enrolled in each vaccine group) of each age group

  7. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second dose in adolescent participants

    Seroresponse defined as post-second vaccination titers ≥ 1:16 for participants with pre-vaccination hSBA titers \< 1:4 or post-second vaccination titers ≥ 4 times the pre-vaccination titer for participants with a pre-vaccination titer more than or equal to the lower limit of quantification (LLOQ)

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

  8. hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 1 month after the second dose in adolescent participants

    hSBA titers ≥ 1:8

    Time frame: Day 211 (for Group 1 to 7)

  9. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose in adolescent participants

    Geometric mean titers

    Time frame: Day 01 (pre-dose) and Day 31 Day 211 (for Group 1 to 7)

  10. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y in adolescent participants

    Time frame: Day 01 (pre-dose) Day 211 (for Group 1 to 7)

  11. hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after second dose in adolescent participants

    Seroresponse defined as a 4-fold increase in hSBA titers

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

  12. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose 1 and 1 month post-second dose in adolescent participants

    hSBA titers ≥ 1:4 for reference MenB strains

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

  13. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose 1 and 1 month post-second dose in adolescent participants

    hSBA titers ≥ 1:8 for reference MenB strains

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

  14. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose 1 and 1 month post-second dose in adolescent participants

    Geometric mean titers for the reference MenB strains

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

  15. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all serogroups B (reference MenB strains) in adolescent participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

Secondary outcomes

  1. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse at each timepoint

    Seroresponse defined as post-vaccination titers ≥ 1:16 for participants with pre-vaccination titers \< 1:4 or post-vaccination titer ≥ 4 times the pre-vaccination titer for participants with pre-dose 1 vaccination titers more than the lower limit of quantification (LLOQ)

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  2. hSBA meningococcal serogroups A, C, W, and Y antibody titers at each timepoint

    hSBA titers ≥ 1:8 post-vaccination

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  3. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y at each timepoint

    Geometric mean titers

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  4. Percentage of participants with hSBA titers more or equal to LLOQ against each of serogroups A, C, W, and Y at each timepoint

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  5. hSBA meningococcal serogroup B (reference MenB strains) vaccine seroresponse at each timepoint

    Seroresponse defined as a 4-fold increase in hSBA titers

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  6. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 at each timepoint

    hSBA titers ≥ 1:4 for reference MenB strains

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  7. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 at each timepoint

    hSBA titers ≥ 1:8 reference MenB strains

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  8. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) at each timepoint

    Geometric mean titers for reference MenB strains

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  9. Percentage of participants with hSBA composite seroresponse titers more or equal to LLOQ for reference MenB strains for each timepoint

    Time frame: D01 (pre-dose) and D31 (post-dose 1 and pre-dose 2), D61 (post-dose 2), D181 (pre-dose 3) and D211 (post-dose 3) for adults (Group 1-6). D01 (pre-dose) and D31 (post-dose 1), D181 (pre-dose 2) and D211 (post-dose 2) for adolescents (Group 1-7)

  10. hSBA meningococcal serogroup B (reference and additional MenB strains) vaccine seroresponse pre-dose 1 and 1 month post-second and third dose in adolescent participants

    Seroresponse defined as a 4-fold increase in hSBA titers from D01 to post-vaccination for reference and additional MenB strains

    Time frame: Day 01 (pre-dose), Day 61 (post-dose 2) and Day 211 (post-dose 3) (for Group 1 to 6 for adults) and Day 211 (for Group 1 to 7 for adolescents)

  11. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference and additional MenB strains) ≥ 1:4 pre-dose 1 and 1 month post-second and third dose in adolescent participants

    hSBA titers ≥ 1:4 for reference and additional MenB strains

    Time frame: Day 01 (pre-dose), Day 61 (post-dose 2) and Day 211 (post-dose 3) (for Group 1 to 6 for adults) and Day 211 (for Group 1 to 7 for adolescents)

  12. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference and additional MenB strains) ≥ 1:8 pre-dose 1 and 1 month post-second and third dose in adolescent participants

    hSBA titers ≥ 1:8 for reference and additional MenB strains

    Time frame: Day 01 (pre-dose), Day 61 (post-dose 2) and Day 211 (post-dose 3) (for Group 1 to 6 for adults) and Day 211 (for Group 1 to 7 for adolescents)

  13. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference and additional MenB strains) pre-dose 1 and 1 month post-second and third dose in adolescent participants

    Geometric mean titers for reference and additional MenB strains

    Time frame: Day 01 (pre-dose), Day 61 (post-dose 2) and Day 211 (post-dose 3) (for Group 1 to 6 for adults) and Day 211 (for Group 1 to 7 for adolescents)

  14. Percentage of participants with hSBA composite seroresponse titers more or equal to LLOQ reference and additional MenB strains in adolescent participants

    Time frame: Day 01 (pre-dose), Day 61 (post-dose 2) and Day 211 (post-dose 3) (for Group 1 to 6 for adults) and Day 211 (for Group 1 to 7 for adolescents)

  15. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse 1 month after the third dose in adult participants

    Seroresponse defined as post-third vaccination titers ≥ 1:16 for participants with pre-vaccination hSBA titers \< 1:4 or post-third vaccination titers ≥ 4 times the pre-vaccination titer for participants with a pre-vaccination titer more than the lower limit of quantification (LLOQ)

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  16. hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 1 month after the third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  17. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  18. Percentage of participants with hSBA titers more or equal to LLOQ against each of serogroups A, C, W, and Y in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  19. hSBA meningococcal serogroup B (reference MenB strains) seroresponse pre-dose and 1 month after third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  20. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose 1 and 1 month post-third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  21. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose 1 and 1 month post-third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  22. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose 1 and 1 month post-third dose in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

  23. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all serogroups B (reference MenB strains) in adult participants

    Time frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 6)

07

Study locations

47 sites
  • Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080
    Birmingham, Alabama 35216, United States
  • Lakeview Clinical Research Site Number : 8400029
    Guntersville, Alabama 35976-2206, United States
  • Alliance for Multispecialty Research- Phoenix- Site Number : 8400056
    Tempe, Arizona 85281, United States
  • Harrisburg Family Medical Center Site Number : 8400070
    Harrisburg, Arkansas 72432, United States
  • Smart Cures Clinical Research Site Number : 8400072
    Anaheim, California 92806, United States
  • Hope Clinical Research, LLC- Site Number : 8400001
    Canoga Park, California 91303, United States
  • Apex Research Group Site Number : 8400071
    Fair Oaks, California 95628, United States
  • Velocity Clinical Research-Washington DC Site Number : 8400102
    Washington D.C., District of Columbia 20016, United States
  • Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400081
    DeLand, Florida 32720-0834, United States
  • SIMEDHealth, LLC- Site Number : 8400045
    Gainesville, Florida 32607, United States
  • Accel Research Sites-St. Petersburg-Largo- Site Number : 8400082
    Largo, Florida 33777, United States
  • South Florida Research Organization Site Number : 8400086
    Medley, Florida 33166, United States
  • Life Arc Research-Miami Site Number : 8400094
    Miami, Florida 33126, United States
  • Charisma Medical and Research center Site Number : 8400097
    Miami Lakes, Florida 33014, United States
  • Accel Research - Nona Pediatric Center Site Number : 8400079
    Orlando, Florida 32829, United States
  • Ormond Beach Clinical Research- Site Number : 8400073
    Ormond Beach, Florida 32174, United States
  • Palm Harbor Dermatology- Site Number : 8400030
    Tampa, Florida 33609, United States
  • PAS Research Site Number : 8400032
    Tampa, Florida 33613, United States
  • VICIS Clinical Research-Tampa Site Number : 8400065
    Tampa, Florida 33614, United States
  • Leavitt Clinical Research-Idaho Falls- Site Number : 8400075
    Idaho Falls, Idaho 83404, United States
  • Snake River Research, PLLC- Site Number : 8400100
    Idaho Falls, Idaho 83404, United States
  • AES Peoria- Site Number : 8400090
    Peoria, Illinois 61614, United States
  • AMR Evansville Site Number : 8400062
    Evansville, Indiana 47712, United States
  • AMR - Newton- Site Number : 8400104
    Newton, Kansas 67114, United States
  • ~Kentucky Pediatics / Adult Research- Site Number : 8400009
    Bardstown, Kentucky 40004, United States
  • Michael W. Simon, MD, PSC- Site Number : 8400026
    Lexington, Kentucky 40517, United States
  • Vida Clinical Studies Site Number : 8400084
    Dearborn Heights, Michigan 48127-2234, United States
  • Vida Clinical Studies- Site Number : 8400084
    Dearborn Heights, Michigan 48127-2234, United States
  • Be Well Clinical Studies- Site Number : 8400077
    Lincoln, Nebraska 68516, United States
  • Alivation Research (Primary Care) Site Number : 8400046
    Lincoln, Nebraska 68526, United States
  • Quality Clinical Research, Inc.- Site Number : 8400074
    Omaha, Nebraska 68114, United States
  • Velocity Clinical Research, Omaha- Site Number : 8400066
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research-Albuquerque- Site Number : 8400101
    Albuquerque, New Mexico 87107, United States
  • Prime Global Research, Inc. Site Number : 8400043
    The Bronx, New York 10456, United States
  • Monroe Biomedical Research - Site Number : 8400099
    Monroe, North Carolina 28112, United States
  • SPICA Clinical Research Site Number : 8400098
    Columbia, South Carolina 29223, United States
  • Coastal Carolina Research Center - N Charleston- Site Number : 8400050
    North Charleston, South Carolina 29405, United States
  • Tribe Clinical Research at Parkside Pediatrics-Five Forks Site Number : 8400049
    Simpsonville, South Carolina 29681, United States
  • Pediatric Clinical Trials Tullahoma- Site Number : 8400020
    Tullahoma, Tennessee 37388, United States
  • New Horizon Medical Group-Houston Site Number : 8400069
    Houston, Texas 77063, United States
  • DM Clinical Research- Bellaire- Site Number : 8400052
    Houston, Texas 77081, United States
  • Advances in Health- Pearland- Site Number : 8400078
    Pearland, Texas 77584, United States
  • Be Well Clinical Studies -Round Rock Site Number : 8400053
    Round Rock, Texas 78681, United States
  • Progressive Clinical Research- Site Number : 8400028
    Bountiful, Utah 84010, United States
  • AMR Utah-Wee Care Pediatrics-Kaysville- Site Number : 8400106
    Kaysville, Utah 84037, United States
  • Alliance for Multispecialty Research- Site Number : 8400107
    Murray, Utah 84107, United States
  • Investigational Site Number : 6300001
    San Juan, 00918, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Aug 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 13, 2023
StartActual
Oct 31, 2023
Primary completionActual
Aug 27, 2025
CompletionActual
Aug 27, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128733
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 31, 2023
Primary completion
Aug 27, 2025
Completion
Aug 27, 2025
Last update
Jan 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion